Use of Radioguided Surgery for Small and Difficult-to-Locate Relapsed MIBG (+) High-Risk Neuroblastoma Lesions

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Oct 16

PMID 39409967

Authors

Lucas Krauel

Albert Pasten

Maite Gorostegui

Salvador Mane

Marta Pilar Martin Gimenez

Maria Coronas

Rosalia Carrasco Torrents

Jaume Mora

Affiliations

Soon will be listed here.

Abstract

Introduction: High-risk neuroblastoma, particularly in the relapse/refractory (R/R) setting, poses unique challenges to obtaining the representative-quality tissue that is mostly required for molecular analysis. This study explores the use of 123I-MIBG radioguided surgery to access complex locations of MIBG-positive neuroblastoma as a tool to overcome the difficulties associated with repeated surgeries in these patients.

Methods: This study is a retrospective review of all patients with R/R neuroblastoma and MIBG-uptaking lesions who underwent radioguided surgery between February 2020 and 2023 at SJD Barcelona Children's Hospital. The Europrobe 3.2 gamma probe was used to identify neuroblastoma tissue in the operating room.

Results: Ten patients were identified. Radioguided surgery was useful in all patients. One patient with previous multiple operations developed an entero-cutaneous fistula with posterior full recovery. Mean surgical time was 111.7 min. The gamma probe identified 100% of neuroblastoma lesions which were all completely removed (123I-MIBG-SPECT/CT negative post-surgery). Pathology and molecular studies could be successfully performed in all samples.

Conclusions: 123I-MIBG radioguided surgery proved effective in obtaining viable tissue from difficult-to-access sites in high-risk relapsed neuroblastoma.

References

Yoneda A . Role of surgery in neuroblastoma. Pediatr Surg Int. 2023; 39(1):177. DOI: 10.1007/s00383-023-05459-1. View

Ihrmark Lundberg K, Treis D, Johnsen J . Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies. Curr Oncol Rep. 2022; 24(8):1053-1062. PMC: 9249718. DOI: 10.1007/s11912-022-01270-8. View

Martelli H, Ricard M, Larroquet M, Wioland M, Paraf F, Fabre M . Intraoperative localization of neuroblastoma in children with 123I- or 125I-radiolabeled metaiodobenzylguanidine. Surgery. 1998; 123(1):51-7. View

Pio L, Guerin F, Martucci C, Martelli H, Gauthier F, Branchereau S . The Use of Cavitron Ultrasonic Surgical Aspirator for High-Risk Neuroblastoma with Image-Defined Risk Factors in Children. Children (Basel). 2023; 10(1). PMC: 9857095. DOI: 10.3390/children10010089. View

Rosswog C, Fassunke J, Ernst A, Schomig-Markiefka B, Merkelbach-Bruse S, Bartenhagen C . Genomic ALK alterations in primary and relapsed neuroblastoma. Br J Cancer. 2023; 128(8):1559-1571. PMC: 10070426. DOI: 10.1038/s41416-023-02208-y. View

Chung C, Boterberg T, Lucas J, Panoff J, Valteau-Couanet D, Hero B . Neuroblastoma. Pediatr Blood Cancer. 2021; 68 Suppl 2:e28473. PMC: 8785544. DOI: 10.1002/pbc.28473. View

Mora J, Castaneda A, Colombo M, Gorostegui M, Gomez F, Mane S . Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma. Cancers (Basel). 2021; 13(6). PMC: 7998131. DOI: 10.3390/cancers13061264. View

Mora J . Autologous Stem-Cell Transplantation for High-Risk Neuroblastoma: Historical and Critical Review. Cancers (Basel). 2022; 14(11). PMC: 9179268. DOI: 10.3390/cancers14112572. View

Adams S, Baum R, Hertel A, Wenisch H, Herrmann G, Encke A . Intraoperative gamma probe detection of neuroendocrine tumors. J Nucl Med. 1998; 39(7):1155-60. View

10.

Bleeker G, Tytgat G, Adam J, Caron H, Kremer L, Hooft L . 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database Syst Rev. 2015; (9):CD009263. PMC: 4621955. DOI: 10.1002/14651858.CD009263.pub2. View

11.

Povoski S, Neff R, Mojzisik C, OMalley D, Hinkle G, Hall N . A comprehensive overview of radioguided surgery using gamma detection probe technology. World J Surg Oncol. 2009; 7:11. PMC: 2653072. DOI: 10.1186/1477-7819-7-11. View

12.

Chan G, Chan C . Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma. Biomolecules. 2022; 12(3). PMC: 8945428. DOI: 10.3390/biom12030358. View

13.

Boekestijn I, van Oosterom M, Delloglio P, van Velden F, Pool M, Maurer T . The current status and future prospects for molecular imaging-guided precision surgery. Cancer Imaging. 2022; 22(1):48. PMC: 9446692. DOI: 10.1186/s40644-022-00482-2. View

14.

Avanzini S, Pio L, Erminio G, Granata C, Holmes K, Gambart M . Image-defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy-induced variation, and impact on surgical outcomes. Pediatr Blood Cancer. 2017; 64(11). DOI: 10.1002/pbc.26605. View

15.

Newman E, Abdessalam S, Aldrink J, Austin M, Heaton T, Bruny J . Update on neuroblastoma. J Pediatr Surg. 2018; 54(3):383-389. DOI: 10.1016/j.jpedsurg.2018.09.004. View

16.

Mabe N, Huang M, Dalton G, Alexe G, Schaefer D, Geraghty A . Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1. Nat Cancer. 2022; 3(8):976-993. PMC: 10071839. DOI: 10.1038/s43018-022-00405-x. View

17.

Qiu B, Matthay K . Advancing therapy for neuroblastoma. Nat Rev Clin Oncol. 2022; 19(8):515-533. DOI: 10.1038/s41571-022-00643-z. View

18.

Heij H, Rutgers E, de Kraker J, Vos A . Intraoperative search for neuroblastoma by MIBG and radioguided surgery with the gamma detector. Med Pediatr Oncol. 1997; 28(3):171-4. DOI: 10.1002/(sici)1096-911x(199703)28:3<171::aid-mpo2>3.0.co;2-g. View

19.

Olecki E, Grant C . MIBG in neuroblastoma diagnosis and treatment. Semin Pediatr Surg. 2020; 28(6):150859. DOI: 10.1016/j.sempedsurg.2019.150859. View

20.

Kitamura Y, Baba S, Isoda T, Maruoka Y, Sasaki M, Kamitani T . I metaiodobenzylguanidine (MIBG) uptake predicts early relapse of neuroblastoma using semi-quantitative SPECT/CT analysis. Ann Nucl Med. 2021; 35(5):549-556. PMC: 8079305. DOI: 10.1007/s12149-021-01595-7. View